RECURRENT GLIOBLASTOMA
Clinical trials for RECURRENT GLIOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOBLASTOMA trials appear
Sign up with your email to follow new studies for RECURRENT GLIOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New gene therapy aims to turn the body against deadly brain cancer
Disease control Not yet recruitingThis study is testing a new gene therapy called TGX-007 for people with a fast-growing type of brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two treatments directly into the tumor: one to kill cancer cells and another to activate the patient's own…
Matched conditions: RECURRENT GLIOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Trogenix ltd • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for deadly brain cancer: experimental drug enters human trials
Disease control Not yet recruitingThis early-stage trial is testing a new drug called LMP744 in adults whose aggressive brain cancer (glioblastoma) has returned after standard treatment. The main goal is to see if the drug can shrink tumors and slow the cancer's progression. Participants will receive the drug thr…
Matched conditions: RECURRENT GLIOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC
-
Scientists test 'T cell Engager' to fight deadly brain tumors
Disease control Not yet recruitingThis is a first-in-human study to test the safety of a new drug called BRiTE in adults with a specific, aggressive form of brain cancer (glioblastoma). The drug is designed to guide the patient's own immune cells to attack the tumor. The study will enroll up to 18 patients whose …
Matched conditions: RECURRENT GLIOBLASTOMA
Phase: PHASE1 • Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP • Aim: Disease control
Last updated Mar 02, 2026 15:22 UTC